scholarly journals Effect of Nedocromil Sodium on Aspecific Bronchial Hyper-Reactivity in Asthmatic Children

1994 ◽  
Vol 3 (7) ◽  
pp. S43-S47 ◽  
Author(s):  
A. Fiocchi ◽  
P. Signoroni ◽  
P. Bruni ◽  
M. Galeone ◽  
E. DeCet ◽  
...  
Keyword(s):  
Viral Infections ◽  
Tertiary Care ◽  
Nedocromil Sodium ◽  
Atmospheric Pollutants ◽  
Double Blind Study ◽  
Double Blind ◽  
Ultrasonic Nebulization ◽  
Asthmatic Children ◽  
Parallel Group ◽  
Perennial Allergens

The purpose of this study was to evaluate whether nedocromil sodium benefits urban asthmatic children showing seasonal bronchial hyper-reactivity to ultrasonic nebulization of distilled water (UNDW). A prospective, randomized, placebo-controlled, parallel-group, double-blind study was carried out at the outpatient pulmonology service at a tertiary-care teaching hospital. Twelve children living in Milan, who were 7–17 years of age, who were SPT and RAST-negative to perennial allergens, who were suffering from episodic asthma, and showing seasonal bronchial hyper-reactivity to UNDW during winter, participated in this study. All the children received either placebo or nedocromil sodium, 4 mg every 6 h for 6 weeks. Spirometry and UNDW challenge were done at the following times: day−7; day 0; day 1; day 7; day 14; day 28; day 42. No differences were found in the basal spirometric parameters, which were normal in both nedocromil and placebo groups. Bronchial reactivity to UNDW was found to be significantly decreased in the group treated with nedocromtl starting from day 7. It is therefore concluded that nedocromil sodium can reverse bronchial hyper-reactivity caused by seasonal factors such as cold, viral infections and atmospheric pollutants in children suffering from asthma.

A Parallel-Group Comparison of Astemizole and Loratadine for the Treatment of Perennial Allergic Rhinitis

1997 ◽  
Vol 25 (4) ◽  
pp. 175-181 ◽  
Author(s):  
H Al-Muhaimeed
Keyword(s):  
Allergic Rhinitis ◽  
Statistical Significance ◽  
Double Blind Study ◽  
Perennial Allergic Rhinitis ◽  
Double Blind ◽  
Once Daily ◽  
Runny Nose ◽  
Parallel Group ◽  
The Mean ◽  
To Receive

The efficacy and safety of the two antihistamines, astemizole and loratadine, were compared in a double-blind study of 84 patients with perennial allergic rhinitis. Patients were randomized to receive orally either astemizole 10 mg once daily ( n = 40) or loratadine 10 mg once daily ( n = 44) for 1 week. No other antirhinitis medication was allowed during the study. By day 7 the mean daily symptom scores, recorded on diary cards, were lower in patients receiving astemizole than in those receiving loratadine for runny nose, itchy nose and sneezing, although not for blocked nose, and treatment differences only reached statistical significance for runny nose. After 7 days, 53.75% of patients on astemizole and 38.6% on loratadine were free of symptoms, and 87% of patients on astemizole described the treatment as good or excellent compared with 62% on loratadine. The present results suggest that astemizole may be more effective than loratadine in controlling symptoms of perennial allergic rhinitis.

Intravenous dexketoprofen vs placebo for migraine attack in the emergency department: A randomized, placebo-controlled trial

Cephalalgia ◽  
2015 ◽  
Vol 36 (2) ◽  
pp. 179-184 ◽  
Author(s):  
Faruk Gungor ◽  
Kamil Can Akyol ◽  
Mustafa Kesapli ◽  
Ahmet Celik ◽  
Adeviye Karaca ◽  
...  
Keyword(s):  
Emergency Department ◽  
Controlled Trial ◽  
Tertiary Care ◽  
Study Drug ◽  
Final Analysis ◽  
Allocation Concealment ◽  
Double Blind Study ◽  
Care Hospital ◽  
Double Blind ◽  
Migraine Headaches

Objective Migraine is a leading headache etiology that frequently presents to the emergency department (ED). In the present study, we aimed to determine the efficacy of dexketoprofen in aborting migraine headaches in the ED. Methods This prospective, randomized, double-blind study was conducted in an ED of a tertiary care hospital using allocation concealment. Patients were allocated into two arms to receive the study drug; 50 mg dexketoprofen in 50 ml saline and 50 ml saline as placebo. Change in pain intensity was measured by the visual analog scale at baseline, both at 30 and 45 minutes after the study medication was administered. Rescue medication requirement and pain relapse were also recorded by a telephone follow-up at 48 hours. Results A total of 224 patients (112 in each group) were included into the final analysis. Mean age of the study participants was 37 ± 11 (SD) and 25% ( n = 56) of them were male. The median pain improvement at 45 minutes for patients receiving dexketoprofen was 55 (IQR: 49 to 60) and 30 (IQR: 25 to 35) for those receiving placebo. The mean difference between the two groups at 45 minutes was 21.4 (95% CI: 14.4. to 28.5). Rescue drugs were needed in 22.3% of patients who received dexketoprofen compared to 55.4% in patients who received placebo (dif: 33.1%; 95% CI: 20% to 45%). There were no adverse events reported in either group during the study period. Conclusion Intravenous dexketoprofen is superior to placebo in relieving migraine headaches in the ED. It may be a suitable therapy with minimum side effects in patients presenting with a migraine headache to the ED.

Ciprofloxacin plus fluocinolone acetonide versus ciprofloxacin alone in the treatment of diffuse otitis externa

2014 ◽  
Vol 128 (7) ◽  
pp. 591-598 ◽  
Author(s):  
J Lorente ◽  
F Sabater ◽  
M P Rivas ◽  
J Fuste ◽  
J Risco ◽  
...  
Keyword(s):  
Adverse Events ◽  
Clinical Cure ◽  
Otitis Externa ◽  
Fluocinolone Acetonide ◽  
Double Blind Study ◽  
Double Blind ◽  
Parallel Group ◽  
Excellent Safety Profile ◽  
The Mean ◽  
Ear Drops

AbstractObjective:We aimed to evaluate the clinical efficacy of ciprofloxacin plus fluocinolone acetonide (antibiotic plus corticosteroid) ear drops compared to ciprofloxacin (antibiotic) ear drops in diffuse otitis externa.Methods:This was a multicentre, randomised, parallel-group, double-blind study involving 590 patients of both sexes aged 7 years or older.Results:The rate of clinical cure was higher (p = 0.01) with ciprofloxacin plus fluocinolone acetonide than with ciprofloxacin alone. The mean total symptom score was lower with ciprofloxacin plus fluocinolone acetonide (p = 0.005). No differences were found in the percentage of patients reporting resolution of otalgia between patients receiving ciprofloxacin plus fluocinolone acetonide and patients receiving only ciprofloxacin. Resolution of oedema and otorrhoea (p = 0.003 and p = 0.002, respectively) was higher with ciprofloxacin plus fluocinolone acetonide, as was eradication or presumed eradication (p = 0.003). There were eight mild adverse events, three with the ciprofloxacin plus fluocinolone acetonide combination (not related to the treatment) and five when ciprofloxacin was administered alone (directly related to the treatment).Conclusions:Ciprofloxacin plus fluocinolone acetonide is a more effective treatment for diffuse otitis externa than ciprofloxacin alone. The ciprofloxacin plus fluocinolone acetonide combination also has an excellent safety profile.

scholarly journals Effects of Atmospheric Pollutants on Children Asthma Outbreaks

2009 ◽  
Vol 2 (1) ◽  
pp. 9-15 ◽  
Author(s):  
Ben Zion Garty ◽  
Evsey Kosman ◽  
Eliezer Ganor ◽  
Niv Alon ◽  
Neta Kibilis ◽  
...  
Keyword(s):  
Negative Correlation ◽  
Air Pollutants ◽  
Viral Infections ◽  
Airborne Pollen ◽  
Medical Center ◽  
Weather Conditions ◽  
Atmospheric Pollutants ◽  
Asthmatic Children ◽  
School Year ◽  
Weather Parameters

The effects of air pollutants, weather conditions, airborne pollen and spores on the incidence of emergency room (ER) visits of children for acute asthma attacks were investigated. One-year retrospective study was done. Data on daily concentrations of air pollutants, airborne allergens and weather conditions were collected and compared with the ER visits of 2431 asthmatic children (age 1-18 years) in the Schneider Medical Center, near Tel Aviv. ER visits of asthmatic children showed a negative correlation with the measured O3 concentrations and with extreme ambient temperatures. A positive correlation was found with high barometric pressure with NO2 and SO2 concentrations. An exceptionally high incidence of ER visits of asthmatic children was observed during September, coinciding with the beginning of the school year. When September was excluded from the annual calculations the correlation between ER visits and environmental factors increased. 49% of the variance of ER visits were explained by O3 alone, 46% by NO2 alone, 54% by O3+NO2, and 31% by weather parameters. 58% of the variation was explained by the combination of air pollutants and weather parameters. Airborne particulates did not show any meaningful correlation with ER visits. The major factors associated with severe asthma attacks were high NO2 and SO2. The negative correlation with O3 implies that at certain concentrations, O3 may have a beneficial effect. The particularly high number of ER visits at the beginning of the school year was presumably associated with an increase in viral infections combined with emotional stresses.

scholarly journals A Randomized, Placebo-controlled, Double-blind Study on the Effects of SZL on Patients With Mild to Moderate Depressive Disorder With Comparison to Fluoxetine

2020 ◽  
Author(s):  
yuan hu ◽  
yichen wang ◽  
chao chen ◽  
wenshan yang ◽  
weiyu zhu ◽  
...  
Keyword(s):  
Depressive Disorder ◽  
Depression Scale ◽  
Double Blind Study ◽  
Double Blind ◽  
Moderate Depression ◽  
Parallel Group ◽  
Clinical Presentations ◽  
Significant Difference ◽  
To Receive ◽  
Target Effects

Abstract Objective: Kaixinsan (KXS) decoction, as an ancient’s herbal formula, has been demonstrated to be active in various animal models resembling human depression with multi-target effects. This very first study evaluated the efficacy and tolerability of Shen Zhi Ling (SZL) tables (KXS preparation), compared with fluoxetine (FLX, positive comparator), in patients with mild to moderate depressive disorder.Methods: In this randomized double-blind parallel-group study, 156 patients with mild to moderate depression without taken any antidepressants in the past 6 months or 4 straight weeks were randomized to receive either 3.2g/d SZL plus 20mg/d FLX placebo (SZL group) or 20mg/d FLX plus 3.2g/d SZL placebo (FLX group), for 8 weeks. Their clinical presentations and some metabolic indexes were assessed during the 8 weeks visiting period.Results: Patients in SZL group showed a statistically significant improvement after 8 weeks of treatment in HAMD-17 score (18.79±2.09 to 4.43±4.71, p<0.001) and self-rating depression scale (SDS) score (58.49±8.89 to 39.84±12.09, p<0.001), but not in N-back total respond time (1145.55±608.26 to 1128.47±387.49, p>0.05). In addition, no significant difference at 8 weeks of treatment was found between SZL and FLX groups in SDS score (39.84±12.09 vs. 36.63±12.44) and N-back respond time (1128.47±387.49 vs. 1089.43±352.08) as well as reduction of HAMD-17 score (14.79±4.88 vs. 15.24±4.29) (p>0.05 for all). However, the serum APOB, APOC3 and ALB levels and HDL-C/LDL-C ratio decreased significantly in patients after SZL treatment, while only APOB/APOA1 ratio decreased significantly in FLX group. Other metabolic indexes did not alter significantly after treated with SZL or FLX.Conclusion: The efficacy and safety profile of SZL are comparable to that of fluoxetine in patients with mild to moderate depression. The beneficial effect of SZL is probably associated with improvement of lipid metabolic balance.

A randomized, double-blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome

1996 ◽  
Vol 11 (2) ◽  
pp. 93-99 ◽  
Author(s):  
GB Cassano ◽  
A Petracca ◽  
C Borghi ◽  
S Chiroli ◽  
G Didoni ◽  
...  
Keyword(s):  
Placebo Group ◽  
Withdrawal Syndrome ◽  
Adjustment Disorder ◽  
Generalized Anxiety ◽  
Double Blind Study ◽  
Double Blind ◽  
Treatment Allocation ◽  
Parallel Group ◽  
Benzodiazepine Withdrawal ◽  
One Year

SummaryThe aim of the trial was to assess alpidem efficacy in preventing and treating the benzodiazepine (BZ) withdrawal syndrome (WS). A multicentre, double-blind, randomized versus placebo, parallel group study of six-week duration was carried out in outpatients suffering from generalized anxiety or adjustment disorder with an anxious mood and taking non-hypnotic BZ as continuous course of therapy of at least one-year duration. At the entry, the patients abruptly discontinued BZs and were treated with 50 mg/bid/tid of alpidem or placebo. Withdrawal syndrome diagnosis was (regarding treatment allocation) formulated by an independent psychiatrist, according to DSM-III-R and an appropriate scale, the SESSB. One hundred seventy-three patients were randomized and 148 completed the study. Withdrawal syndrome occurred in 27 patients of the alpidem group (31.0%) and in 38 patients of the placebo group (44.2%). A severe WS was diagnosed in 11.1% of the patients in the alpidem group and in 31.6% of the placebo group. If not having been withdrawn from the market, alpidem could have been useful for the prevention of BZ withdrawal syndrome.

Sign in / Sign up

Export Citation Format

Share Document